Skip to main content
. Author manuscript; available in PMC: 2023 Sep 13.
Published in final edited form as: Breast Cancer Res Treat. 2023 Jun 16;201(1):117–126. doi: 10.1007/s10549-023-06997-x

Table 2.

Hazard rate ratios and 95% confidence intervals of incident cardiometabolic risk factors women with hormone-receptor positive breast cancer with history of endocrine therapy use relative to non-endocrine therapy use

Premenopausal Postmenopausal
Cardiometabolic Risk Factor Non-users of Endocrine Therapy, n=260 Tamoxifen Users, n=1,212 Non-users of Endocrine Therapy, n=1,179 Tamoxifen Users, n=546 Aromatase Inhibitor Users, n=5,788
Diabetes
 Total events 10 95 64 36 533
 Total Person-Years 2,255.5 9,788.7 6,944.0 3,595.0 33,370.6
 Incidence Rate per 1,000 person-years 4.43 9.71 9.22 10.01 15.97
 Unadjusted model, HR (95%CI) Referent 2.15 (1.12, 4.12) Referent 1.15 (0.77, 1.73) 1.74 (1.34, 2.25)
 Adjusted model1, HR (95%CI) Referent 1.65 (0.83, 3.25) Referent 1.22 (0.79, 1.89) 1.37 (1.05, 1.80)
Dyslipidemia
 Total events 26 150 121 60 846
 Total Person-Years 1,879.1 8,667.9 3,537.0 1,903.8 13,630.6
 Incidence Rate per 1,000 person-years 13.84 17.31 34.21 31.52 62.07
 Unadjusted model, HR (95%CI) Referent 1.24 (0.81, 1.87) Referent 0.96 (0.71, 1.31) 1.62 (1.34, 1.96)
 Adjusted model1, HR (95%CI) Referent 1.23 (0.80, 1.90) Referent 0.92 (0.67, 1.27) 1.58 (1.29, 1.92)
Hypertension
 Total events 34 160 132 81 874
 Total Person-Years 1,934.8 8,376.4 2,897.9 1,681.2 13,123.6
 Incidence Rate per 1,000 person-years 17.57 19.10 45.55 48.18 66.60
 Unadjusted model, HR (95%CI) Referent 1.07 (0.74, 1.55) Referent 1.13 (0.86, 1.49) 1.39 (1.16, 1.67)
 Adjusted model1, HR (95%CI) Referent 1.07 (0.72, 1.58) Referent 1.43 (1.06, 1.92) 1.50 (1.24, 1.82)
1

Adjusted for age, race/ethnicity, smoking status, AJCC stage, body mass index, chemotherapy, radiation therapy, breast surgery, and prevalent (baseline) diabetes, dyslipidemia, and hypertension (when not the outcome of interest).